Yeah, capital market structure is so f-ed up for mid-stage biotech/pharma. (But we're working on it!) It looks like in this case there were also other regulatory + market frictions that seem to have made antibiotic drug development in particular more challenging. But yes, scary!
This is a scary read. I don't know much about the space, but if the incentives for developing new antibiotics are this messed up, we're in trouble.https://twitter.com/JohnCendpts/status/1205516175528075272 …
-
-
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
As long as we align profit with drug development we’ll run into this kind of problems. Government and public entities should regulate and put money into drug development based on healthcare needs and not profit. That’s a hard sell in the US though.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.